Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

We assessed safety and efficacy of rituximab in a prospective study of 36 patients, age 2.6 to 18.3 years, with severe chronic immune thrombocytopenic purpura (ITP). The primary outcome of sustained platelets above 50 × 10(9)/L (50 000/mm(3)) during 4 consecutive weeks, starting in weeks 9 to 12, wa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bennett, Carolyn M., Rogers, Zora R., Kinnamon, Daniel D., Bussel, James B., Mahoney, Donald H., Abshire, Thomas C., Sawaf, Hadi, Moore, Theodore B., Loh, Mignon L., Glader, Bertil E., McCarthy, Maggie C., Mueller, Brigitta U., Olson, Thomas A., Lorenzana, Adonis N., Mentzer, William C., Buchanan, George R., Feldman, Henry A., Neufeld, Ellis J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: The American Society of Hematology 2006
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895391/
https://ncbi.nlm.nih.gov/pubmed/16352811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-08-3518
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller